Research evidence / Overview of studies for Proair Bronquial
Evidence for Use in Asthma
Research describing the use of this combination product for persistent asthma primarily involves extensive Randomized Controlled Trials (RCTs). These are supported by systematic reviews and meta-analyses that combine results from many different trials to provide a broader view. Studies have been conducted on adults, adolescents, and children (as young as 4 years old) whose asthma was not well-managed by an Inhaled Corticosteroid (ICS) alone.
The research examined several core outcomes related to physical discomfort. Studies monitored pulmonary function measures, such as how much air a person can forcefully exhale in one second (FEV1), to see if there were changes measured during the study period related to airflow. Researchers also studied the rate of severe asthma exacerbations, which are episodes of heightened symptom activity requiring emergency care or oral steroid use, and measured how often patients needed to use their short-acting rescue inhalers.
Findings describe patterns observed in the studies over follow-up durations that typically ranged from a few months up to one year. Research highlights changes measured in FEV1 and patterns of observed exacerbation frequency in trials that included the Inhaled Corticosteroid component alone as a comparator group. However, findings also indicate that results apply only to the specific populations studied, and that certain research focused more on short-term functional endpoints rather than long-term clinical outcomes.
Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)
The combination product was studied for its use in patients requiring long-term treatment for conditions characterized by functional limitations and cycles of stability and flare-ups, specifically in patients with moderate to severe COPD. Evidence for this indication is based on a body of large-scale RCTs, some of which studies explored outcomes over extended periods, with follow-up durations up to three years.
Research examined several outcomes related to systemic or functional imbalance. Primary study outcomes included the annual rate of severe COPD exacerbations, which are acute or disruptive episodes that place physiological strain on the patient. Other studies monitored changes in pulmonary function over time and outcomes reflecting daily functioning or activity level, using specific health status questionnaires.
Large trials reported data showing patterns related to the observed annual rate of exacerbations in the observed populations in trials that included placebo or individual component therapies as comparator groups. Evidence indicates that these findings are derived from substantial, multi-year clinical trial data, contributing to the broader evidence landscape. However, research exploring short-term symptom changes, like dyspnea (shortness of breath), sometimes reported mixed findings in certain population subgroups.
Studies on Long-Term Outcomes and Follow-Up Duration
Studies monitored the responses of patients over defined time intervals that varied by indication. For asthma, the pivotal trials primarily relied on intermediate-term follow-up durations, typically ranging up to one year. In COPD research, however, there are large, multi-center trials where the studies monitored outcomes over periods as long as three years.
These longer-term research scenarios provided insight into outcomes observed over extended treatment durations. While these multi-year studies exist, the long-term effects are not fully established beyond the observed duration of the clinical trials. Research helps contextualize how patients reported their experience during the study period, but it does not determine whether an individual will respond similarly over a lifetime of use.
Research in Specific Populations
Research was conducted on children with asthma, with studies including populations as young as 4 years old. These trials explored the use of the combination product in this age group, measuring their response in terms of pulmonary function and symptom patterns. Findings describe group patterns, but research provides context but not individual predictions for this special population.
For COPD, the data primarily stems from patients with moderate to severe disease who are often older and have a history of smoking. This means that results apply only to the populations studied.
Scientific Gaps and Areas of Uncertainty
Research has explored various aspects of the combination product, but data for certain groups remain insufficient. For instance, patients with very mild asthma or early-stage, asymptomatic COPD are not well-represented in the pivotal trials, meaning the results apply only to the populations studied (those with persistent or moderate-to-severe disease).
Furthermore, while the combination of an ICS and a LABA was studied for specific outcomes, comparative evidence is lacking for a full assessment against every other ICS/LABA product on the market. Also, some of the initial studies focused mainly on short-term changes, and the long-term effects are not fully established beyond the observation period of the clinical trials conducted. This means that evidence highlights what is known—and what is still uncertain—about the medicine.
Key Studies & References
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone (AUSTRI Trial)
